Systemic HypertensionSystemic HypertensionСистемные гипертензии2075-082X2542-2189Intermedservice Ltd3316710.26442/SG33167ArticlesСтатьиVozmozhnosti korrektsii giperurikemii lozartanom u patsientov s arterial'noy gipertenziey i podagroyВозможности коррекции гиперурикемии лозартаном у пациентов с артериальной гипертензией и подагройNedogodaS VНедогодаС В

Волгоградский государственный медицинский университет

LedyaevaA AЛедяеваА А

Волгоградский государственный медицинский университет

ChumachokE VЧумачокЕ В

Волгоградский государственный медицинский университет

TsomaV VЦомаВ В

Волгоградский государственный медицинский университет

Волгоградский государственный медицинский университет1512201184NO4 (2011)ТОМ 8, №4 (2011)646813042020Copyright ©; 2011, Consilium MedicumCopyright ©; 2011, ООО "Консилиум Медикум"2011Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.eco-vector.com/2075-082X/article/view/33167

1. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-30.2. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg. Sweden. Acta Med Scand 1988; 224: 549-55.3. Ford ES, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-32.4. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369-79.5. Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975; 37: 1210-5.6. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.7. Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.8. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.9. Bairaktari ET, Kakafika AI, Pritsivelis N et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 2003; 41: 1225-32.10. Riedel A, Nelson M. Prevalence of co morbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10 (6): 308-14.11. Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.12. Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.13. Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.14. Daskalopoulou SS et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66 (4): 1714-5.15. Daijiro U, Hiroaki K. Long-term effects of angiotensin II receptor antagonist losartan on uric acid metabolism in hyperuricemic patients. Gout Nucleic Acid Metab 2002; 26: 25-32.16. Quarantino CP, Di Sciacio N, Rucci C et al. The normal range of serum urate levels and of fractional urate excretion. Adv Exp Med Biol 1994; 370: 91-3.17. Takahashi S, Moriwaki Y. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572-5.